Bacteria cocktail aims to boost cancer immunotherapy
NCT ID NCT04208958
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors better. Researchers measured safety and how many patients saw their tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VE800 (a mix of 11 live bacteria) plus nivolumab (Opdivo)
What this could lead to
If it works, this could point toward a new way to boost the immune system to fight advanced cancers.
What could go wrong
This is an early, small study (56 people) testing safety and response. The bacteria mix may not work for everyone, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor Scott and White Center for Advanced Heart and Lung Disese
Dallas, Texas, 75246, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Huntsman Cancer Institute and Hospital
Salt Lake City, Utah, 84112, United States
-
Indiana University Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
New York University Medical Oncology Associates
New York, New York, 10016, United States
-
Pacific Hematology Oncology Associates
San Francisco, California, 94115, United States
-
Swedish Medical Oncology - First Hill
Seattle, Washington, 98104, United States
-
The Angeles Clinic and Research Institute - West Los Angeles Office
Santa Monica, California, 90404, United States
-
The Miriam Hospital
Providence, Rhode Island, 02906, United States
-
The University of Chicago
Chicago, Illinois, 60637, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of California Los Angeles
Santa Monica, California, 90404, United States
-
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States